KRAZATI (Adagrasib)
Targeted KRAS G12C Inhibitor for Advanced Non-Small Cell Lung Cancer
KRAZATI (adagrasib) is a targeted cancer therapy that works by irreversibly blocking the KRAS G12C mutant protein, a key driver of tumor growth in certain lung cancers. Approved for adults with advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy, KRAZATI represents an important advance in precision oncology for a mutation once considered “undruggable.”
Quick Facts
Key Takeaways
- KRAZATI is a targeted therapy specifically designed for NSCLC patients whose tumors carry the KRAS G12C mutation, confirmed by a validated test.
- The standard dosage is 600 mg (three 200 mg tablets) taken twice daily by mouth, with or without food.
- Common side effects include nausea, diarrhea, fatigue, liver enzyme elevations, and QTc prolongation — regular monitoring is essential.
- Multiple significant drug interactions exist; several medications are absolutely contraindicated with KRAZATI.
- KRAZATI is approved under conditional marketing authorization, with ongoing studies evaluating long-term outcomes.
What Is KRAZATI and What Is It Used For?
KRAZATI (adagrasib) is a prescription cancer medicine that targets and blocks the KRAS G12C mutant protein. It is used to treat adults with advanced non-small cell lung cancer (NSCLC) that has a specific gene change called KRAS G12C, after at least one prior systemic treatment has failed.
KRAZATI contains the active substance adagrasib and belongs to a group of medicines called antineoplastic agents, commonly known as cancer medicines. It is specifically classified as a KRAS G12C inhibitor — a new class of targeted therapies that was developed to address a genetic mutation long considered untreatable in oncology.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80–85% of all lung cancer cases worldwide. Among NSCLC patients, the KRAS G12C mutation is one of the most frequently occurring oncogenic driver mutations, found in approximately 13% of patients with non-squamous NSCLC. This mutation causes the production of an abnormal protein that drives uncontrolled cancer cell growth and proliferation.
KRAZATI is indicated for adults with NSCLC that is locally advanced or has metastasized (spread to other parts of the body), specifically when previous treatments have failed to stop the cancer from growing. Before starting treatment with KRAZATI, your doctor will perform a validated test to confirm that your cancer cells harbor the KRAS G12C mutation, as the drug only works in tumors with this specific genetic alteration.
How Does KRAZATI Work?
The KRAS protein is a crucial molecular switch in cells, regulating signals that control cell growth, differentiation, and survival. In normal cells, KRAS cycles between an active (GTP-bound) and inactive (GDP-bound) state. The G12C mutation causes the protein to become stuck in its active state, sending continuous signals for cell growth and leading to uncontrolled cancer cell proliferation through the RAS-MAPK signaling pathway.
Adagrasib, the active substance in KRAZATI, works by selectively and irreversibly binding to the KRAS G12C protein when it is in its inactive (GDP-bound) state. By forming a covalent bond with the mutant cysteine residue at position 12, adagrasib locks the protein in its inactive conformation. This prevents KRAS G12C from cycling back to its active state, effectively shutting down the oncogenic signaling cascade that drives tumor growth.
What makes KRAZATI particularly notable is its selectivity: it targets only the mutant KRAS G12C protein, not normal (wild-type) KRAS. This targeted approach aims to destroy cancer cells while minimizing damage to healthy tissues. Adagrasib has been designed with a long half-life of approximately 23 hours, allowing it to maintain prolonged target coverage, and has demonstrated the ability to cross the blood-brain barrier, which may provide therapeutic benefit for patients with brain metastases.
Unlike traditional chemotherapy, which attacks all rapidly dividing cells, KRAZATI is a targeted therapy that works specifically against cancer cells with the KRAS G12C mutation. This precision medicine approach was made possible through advances in molecular diagnostics and drug design. The KRAS G12C mutation was first identified in the 1980s but was considered “undruggable” for decades until the development of covalent inhibitors like adagrasib.
What Should You Know Before Taking KRAZATI?
Before starting KRAZATI, your doctor must confirm your KRAS G12C mutation status, review all your current medications for interactions, assess liver and heart function, and evaluate pregnancy status. Several medications are absolutely contraindicated with KRAZATI.
Contraindications
Do not take KRAZATI if you are allergic to adagrasib or any of the other ingredients in this medicine. More importantly, KRAZATI must not be taken together with certain medications because the combination can cause serious and potentially life-threatening adverse effects. The following medicines are absolutely contraindicated with KRAZATI:
- Alfuzosin — used to treat benign prostatic hyperplasia (enlarged prostate)
- Amiodarone — used to treat heart rhythm disorders
- Cisapride — used to treat gastrointestinal conditions
- Pimozide, Quetiapine — antipsychotic medications
- Quinidine — used to treat malaria and heart rhythm problems
- Ergotamine, Dihydroergotamine — used to treat migraine
- Lovastatin, Simvastatin — used to lower blood cholesterol
- Sildenafil — when used for pulmonary arterial hypertension (PAH)
- Triazolam — used to treat insomnia
- Sirolimus, Tacrolimus — used to prevent organ transplant rejection
- Ticagrelor — used to prevent heart attack and stroke
Taking KRAZATI with any of the contraindicated medications listed above can cause serious and potentially life-threatening side effects. Always inform your healthcare provider about every medication you take, including over-the-counter drugs, herbal products, and supplements.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking KRAZATI if you have any of the following conditions or concerns:
Liver toxicity (hepatotoxicity): KRAZATI can affect your liver. Your doctor will perform liver function tests before you start treatment, once a month during the first 3 months of therapy, and thereafter as deemed necessary. Based on the results, your doctor may reduce your dose or discontinue treatment. Signs of liver problems include yellowing of the skin or eyes (jaundice), dark urine, nausea, or upper abdominal pain.
Heart rhythm abnormalities (QTc prolongation): KRAZATI can cause changes in the electrical activity of the heart that affect its rhythm. Tell your doctor before starting treatment if you have heart or circulatory problems, have a history of abnormal heart rhythms, or take any medications that carry a risk of heart rhythm problems. Your doctor will monitor your heart using an electrocardiogram (ECG) and may adjust your KRAZATI dose accordingly.
Gastrointestinal effects: During treatment, inform your doctor if you develop diarrhea, nausea, or vomiting. These are common side effects, and your doctor may decide to reduce the dose, pause treatment, or stop KRAZATI depending on severity.
Severe skin reactions: Serious and potentially life-threatening skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with KRAZATI treatment. Stop taking KRAZATI and seek immediate medical attention if you notice any of the following symptoms:
- Reddish, non-raised, target-like or circular spots on the trunk, often with central blistering
- Peeling or blistering of the skin
- Sores in the mouth, throat, nose, genitals, or eyes
- Widespread skin rash with enlarged lymph nodes
- Fever and flu-like symptoms preceding a skin rash
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy: Do not take KRAZATI if you are pregnant or suspect you may be pregnant, unless your doctor has specifically instructed you to do so. The effects of KRAZATI on pregnant women are not known, and the drug may cause harm to an unborn child based on its mechanism of action. Women of childbearing potential must use effective contraception during treatment with KRAZATI and for at least 5 days after the last dose. Discuss with your doctor which contraceptive method is most suitable for you.
Breastfeeding: Do not breastfeed while receiving treatment with KRAZATI. It is not known whether this medicine passes into breast milk. Given the potential for serious adverse reactions in breastfed infants, breastfeeding should be discontinued during treatment and for a period after the last dose.
Children and Adolescents
KRAZATI has not been studied in children or adolescents. Treatment with KRAZATI is not recommended for persons under 18 years of age.
Driving and Using Machines
KRAZATI may have a minor effect on the ability to drive and use machines. If you feel dizzy, experience vertigo, or feel fatigued, do not drive, operate machinery, or engage in activities that pose a risk to yourself or others until these symptoms resolve.
How Does KRAZATI Interact with Other Drugs?
KRAZATI has numerous clinically significant drug interactions. It is a substrate and inhibitor of CYP3A4, meaning both drugs that affect this enzyme system and drugs metabolized by it may require dose adjustments or avoidance. Always provide your healthcare team with a complete list of all medications and supplements you take.
Drug interactions are a major consideration when prescribing KRAZATI. Adagrasib is both a substrate (it is broken down by certain enzymes) and an inhibitor (it blocks the activity of certain enzymes) of the cytochrome P450 system, particularly CYP3A4. This dual role means that many commonly prescribed medications can either affect KRAZATI levels or be affected by KRAZATI. Understanding these interactions is critical for safe and effective treatment.
Drugs That Decrease KRAZATI Effectiveness
Certain medicines and herbal supplements can reduce how well KRAZATI works by decreasing the amount of adagrasib in the blood. Strong CYP3A4 inducers significantly lower KRAZATI plasma concentrations, potentially rendering the therapy ineffective. These include:
- Rifampicin — used to treat tuberculosis and other infections
- Carbamazepine, Phenobarbital, Phenytoin — used to treat epilepsy
- St. John’s wort (Hypericum perforatum) — a herbal remedy used for mild depression and anxiety
Drugs That Increase KRAZATI Side Effect Risk
Some medicines can increase the risk of side effects from KRAZATI by increasing adagrasib levels in the blood. Strong CYP3A4 inhibitors can significantly raise KRAZATI concentrations, leading to increased toxicity. These include:
- Itraconazole, Ketoconazole, Posaconazole, Voriconazole — antifungal medications
- Clarithromycin, Telithromycin, Troleandomycin — antibiotics
- Ritonavir — used for HIV treatment
Drugs Affected by KRAZATI
Because KRAZATI inhibits CYP3A4, it can increase the blood levels of other medications that are metabolized by this enzyme, potentially causing increased side effects of those drugs. Your doctor will carefully review all concomitant medications.
QTc-Prolonging Drug Interactions
Certain medicines can cause changes in the heart’s electrical conduction, particularly when taken with KRAZATI, which itself carries a risk of QTc prolongation. The following table summarizes key drug categories that may increase this risk:
| Drug Category | Examples | Interaction Type | Risk Level |
|---|---|---|---|
| Antiarrhythmics | Amiodarone, disopyramide, dofetilide, dronedarone, flecainide, sotalol, quinidine | QTc prolongation + CYP3A4 substrate | Contraindicated / High |
| Antibiotics / Antifungals | Azithromycin, ciprofloxacin, clarithromycin, erythromycin, levofloxacin, moxifloxacin, fluconazole | QTc prolongation + CYP3A4 inhibition | High |
| Antimalarials | Chloroquine, halofantrine, hydroxychloroquine | QTc prolongation | High |
| Antipsychotics / Antidepressants | Chlorprothixene, citalopram, escitalopram, haloperidol, sulpiride, pimozide | QTc prolongation + CYP substrate | Contraindicated (pimozide) / High |
| GI Medications | Chlorpromazine, domperidone, droperidol, ondansetron, loperamide | QTc prolongation | Moderate to High |
| CYP3A4 Inducers | Rifampicin, carbamazepine, phenobarbital, phenytoin, St. John’s wort | Reduced KRAZATI efficacy | Avoid concomitant use |
| CYP3A4 Inhibitors | Itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, ritonavir | Increased KRAZATI levels | Avoid or use with caution |
| Other | Anagrelide, cilostazol, bepridil, donepezil, methadone, terfenadine | QTc prolongation | Moderate |
Consuming certain brands of grapefruit juice, especially in large quantities, at the start of KRAZATI treatment may increase the risk of side effects. Grapefruit juice inhibits CYP3A4 in the gut, leading to higher blood levels of adagrasib. Discuss grapefruit consumption with your healthcare provider.
What Is the Correct Dosage of KRAZATI?
The recommended dose of KRAZATI is 600 mg (three 200 mg tablets) taken orally twice daily. Tablets should be swallowed whole with water, with or without food. Your doctor may adjust the dose based on tolerability and side effects.
KRAZATI will be prescribed by a doctor experienced in the use of cancer medicines. Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are unsure about any aspect of your treatment regimen.
Adults
Standard Adult Dosage
Dose: 600 mg (three 200 mg tablets) taken twice daily
Total daily dose: 1,200 mg
Timing: Take at the same time each day, approximately 12 hours apart
With food: Can be taken with or without food
Administration: Swallow tablets whole with water
Do not change your dose unless your doctor or pharmacist tells you to do so. Your doctor may reduce the dose or stop treatment depending on how well you tolerate the medication and any side effects you experience. Dose reductions are typically made in steps (e.g., from 600 mg twice daily to 400 mg twice daily, or further if needed).
Alternative Administration
If you cannot swallow tablets whole, you may disperse them in water using the following method:
- Place your dose of KRAZATI tablets in half a glass (at least 120 mL) of non-carbonated, room-temperature drinking water. Do not crush the tablets. Do not use other liquids, including acidic drinks such as fruit juices.
- Stir thoroughly until the mixture appears white with small tablet fragments. Do not chew the fragments.
- Drink the mixture immediately.
- Rinse the glass with another half glass of water and drink immediately to ensure you have received the full dose.
Children and Adolescents
Pediatric Dosage
KRAZATI has not been studied in children or adolescents under 18 years of age. It is not recommended for use in this population. No dosing information is available for pediatric patients.
Elderly Patients
Elderly Dosage
No specific dose adjustment is required solely based on age. However, elderly patients may be more susceptible to certain side effects such as QTc prolongation, fatigue, and gastrointestinal toxicity. Close monitoring and dose adjustments based on tolerability are recommended.
Missed Dose
If you miss a dose, take it as soon as possible. However, if more than 4 hours have passed since the missed dose, skip it and take your regular dose at the next scheduled time. Do not take a double dose to make up for a forgotten dose.
Overdose
If you take more tablets than recommended, contact your doctor, pharmacist, or nurse immediately. There is no specific antidote for adagrasib overdose, and treatment is symptomatic and supportive.
If you vomit after taking a dose of KRAZATI, do not take an extra dose. Take your next dose at the next scheduled time. Report frequent vomiting to your doctor, as dose adjustment or supportive measures may be needed.
Important: Do not stop taking KRAZATI without talking to your doctor first. It is essential that you continue taking this medicine every day for as long as your doctor instructs you to do so. Stopping treatment prematurely may allow the cancer to progress.
What Are the Side Effects of KRAZATI?
Like all medicines, KRAZATI can cause side effects, although not everybody gets them. The most common side effects include gastrointestinal symptoms (nausea, diarrhea, vomiting), fatigue, liver enzyme elevations, QTc prolongation, and decreased appetite. Serious but less common effects include pneumonitis and severe skin reactions.
Side effects of KRAZATI are classified by how frequently they occur. It is important to be aware of both common and serious side effects so you can report them to your healthcare team promptly. Early detection and management of side effects can help you continue treatment safely and effectively.
Serious Side Effects Requiring Immediate Attention
Contact your doctor or seek emergency medical care immediately if you experience any of the following:
- Heart symptoms: Chest pain, shortness of breath, rapid or pounding heartbeat (signs of QTc prolongation)
- Liver symptoms: Yellowing of skin or eyes, dark urine, severe nausea (signs of hepatotoxicity)
- Lung symptoms: New or worsening shortness of breath, cough (signs of pneumonitis)
- Skin reactions: Target-like spots, widespread blistering, mouth sores, peeling skin (signs of SJS/TEN)
Side Effect Frequency Overview
Very Common
May affect more than 1 in 10 patients
- Nausea
- Diarrhea
- Vomiting
- Fatigue and weakness (asthenia)
- Decreased appetite
- Elevated liver enzymes (ALT, AST) and bilirubin
- QTc prolongation (abnormal heart rhythm)
- Anemia (low red blood cell count)
- Low sodium levels (hyponatremia)
- Dizziness and vertigo
- Elevated creatinine (sign of kidney stress)
- Elevated lipase and/or amylase (pancreatic enzymes)
- Peripheral edema (swelling, especially of ankles and feet)
Common
May affect up to 1 in 10 patients
- Pneumonitis (lung inflammation causing breathlessness and cough)
- Lymphopenia (low levels of lymphocytes, a type of white blood cell)
Understanding QTc Prolongation
QTc prolongation is a very common and potentially serious side effect of KRAZATI. It refers to a change in the heart’s electrical conduction system that can affect the rhythm of your heartbeat. In severe cases, QTc prolongation can lead to dangerous heart rhythm disturbances. Your doctor will monitor your heart using ECG tests at baseline and periodically during treatment. Based on ECG results, your doctor may decide to reduce your dose of KRAZATI or discontinue treatment.
Tell your doctor immediately if you develop chest pain, shortness of breath, a rapid heartbeat, or a pounding sensation in your chest. These may be signs that QTc prolongation is affecting your heart function and requires urgent evaluation.
Understanding Liver Effects
Elevated levels of certain liver enzymes (ALT, AST) and bilirubin are very common during KRAZATI treatment. These are detected through routine blood tests and are signs that the liver is being affected by the medication. Your doctor will order liver function tests before starting treatment, monthly during the first 3 months, and as needed thereafter. If significant elevations occur, your doctor may reduce the dose or discontinue KRAZATI.
Contact your healthcare provider if you notice yellowing of your skin or the whites of your eyes (jaundice), unusually dark urine, persistent nausea, or pain in the upper right area of your abdomen, as these could indicate more serious liver damage.
Reporting Side Effects
It is important to report suspected side effects after the medicine has been authorized. This makes it possible to continuously monitor the benefit-risk balance of the medicine. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store KRAZATI?
Store KRAZATI in its original packaging at room temperature. Keep the bottle tightly closed to protect from moisture. Do not remove the desiccant sachets from the bottle. Keep out of reach of children.
Proper storage of KRAZATI is essential to maintain the medication’s effectiveness and safety. Follow these storage guidelines carefully:
- Temperature: No special temperature requirements. Store at room temperature.
- Packaging: Keep in the original container. KRAZATI is supplied in white, opaque plastic bottles with a white, child-resistant cap and a heat induction seal.
- Moisture protection: The medicine is moisture-sensitive. Keep the bottle tightly closed at all times. Each bottle contains two silica gel desiccant sachets — these must remain in the bottle to protect the tablets. Do not swallow the desiccant sachets.
- Expiry date: Do not use after the expiry date stated on the bottle label and carton after “EXP.” The expiry date refers to the last day of that month.
- Children: Keep this medicine out of the sight and reach of children.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment.
What Does KRAZATI Contain?
Each KRAZATI film-coated tablet contains 200 mg of adagrasib as the active ingredient, along with several inactive ingredients in the tablet core and film coating.
Understanding what your medicine contains can help you identify potential allergens or excipients that may affect you. Below is the complete composition of KRAZATI 200 mg film-coated tablets.
Active Ingredient
Each film-coated tablet contains 200 mg adagrasib.
Inactive Ingredients
Tablet core:
- Microcrystalline cellulose (E 460)
- Mannitol (E 421)
- Crospovidone
- Colloidal anhydrous silica (E 551)
- Magnesium stearate (vegetable origin)
Film coating:
- Hypromellose
- Titanium dioxide (E 171)
- Polydextrose (E 1200)
- Talc (E 553b)
- Maltodextrin
- Medium-chain triglycerides (vegetable origin)
Appearance and Packaging
KRAZATI film-coated tablets are white to off-white and oval-shaped, with a stylized “M” on one side and “200” printed on the other side. The medicine is provided in white, opaque plastic bottles with white, child-resistant caps and heat induction seals. Each bottle contains two silica gel desiccant sachets that must remain in the bottle to protect the tablets from moisture.
Pack sizes: Bottles of 120 or 180 film-coated tablets. Not all pack sizes may be marketed in every country.
Marketing Authorization Holder
Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland.
Frequently Asked Questions About KRAZATI
KRAZATI (adagrasib) is used to treat adults with advanced or metastatic non-small cell lung cancer (NSCLC) that carries a specific genetic mutation called KRAS G12C. It is a targeted therapy prescribed when at least one previous systemic treatment has not been effective. Before starting KRAZATI, a validated diagnostic test must confirm the presence of the KRAS G12C mutation in the tumor.
Unlike traditional chemotherapy, which kills all rapidly dividing cells (both cancerous and healthy), KRAZATI is a targeted therapy that specifically attacks cancer cells with the KRAS G12C mutation. It works by locking the abnormal KRAS G12C protein in its inactive state, thereby blocking the signals that drive cancer cell growth. This precision approach generally results in a different side effect profile compared to conventional chemotherapy.
Yes, KRAZATI can be taken with or without food. The recommended dose is 600 mg (three 200 mg tablets) taken twice daily, approximately 12 hours apart. Tablets should be swallowed whole with water. However, you should avoid consuming large amounts of grapefruit juice, as it may increase KRAZATI blood levels and the risk of side effects.
If you miss a dose, take it as soon as you remember. However, if more than 4 hours have passed since the missed dose, skip it entirely and take your next dose at the regularly scheduled time. Never take a double dose to compensate for a missed one. If you vomit after taking KRAZATI, do not take an extra dose — simply take your next dose at the usual time.
No, KRAZATI (adagrasib) and Lumakras (sotorasib) are different drugs, although both are KRAS G12C inhibitors used for the same type of lung cancer. They have different chemical structures, pharmacokinetic properties, and dosing regimens. Notably, adagrasib has a longer half-life (approximately 23 hours vs. 5 hours for sotorasib) and has demonstrated the ability to cross the blood-brain barrier. Your oncologist will determine which treatment is most appropriate based on your individual circumstances.
While taking KRAZATI, your healthcare team will perform regular monitoring. This includes liver function tests (before treatment starts, monthly for the first 3 months, and as needed afterward), ECG tests to check for QTc prolongation, and blood tests to monitor blood cell counts and electrolytes. You should promptly report any new symptoms such as fatigue, jaundice, heart palpitations, breathing difficulties, or skin reactions to your healthcare provider.
References
- European Medicines Agency (EMA). KRAZATI (adagrasib) — Summary of Product Characteristics. European Public Assessment Report (EPAR). Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). KRAZATI (adagrasib) — Prescribing Information. FDA Approved Drug Products. Available at: www.fda.gov. Accessed January 2026.
- Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation. N Engl J Med. 2022;387(2):120-131. doi:10.1056/NEJMoa2204619.
- Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371-2381. doi:10.1056/NEJMoa2103695.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2026. Available at: www.nccn.org.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Metastatic Non-Small Cell Lung Cancer. Ann Oncol. 2023;34(4):358-376.
- World Health Organization (WHO). International Agency for Research on Cancer. Lung Cancer Fact Sheet. Available at: www.who.int. Accessed January 2026.
- Hallin J, Engstrom LD, Hargis L, et al. The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020;10(1):54-71. doi:10.1158/2159-8290.CD-19-1167.
Editorial Team
This article has been written and reviewed by medical professionals to ensure clinical accuracy and reliability.
Medical Writing
iMedic Medical Editorial Team
Written by medical writers with expertise in oncology and clinical pharmacology, following EMA and FDA prescribing information.
Medical Review
iMedic Medical Review Board
Reviewed by board-certified oncologists and clinical pharmacologists with expertise in targeted cancer therapies and lung cancer treatment.
Evidence Standards
Evidence Level 1A
Based on randomized controlled trials, phase II/III clinical data, EMA EPAR, FDA prescribing information, and NCCN/ESMO guidelines.
Independence
No Commercial Funding
iMedic receives no funding from pharmaceutical companies. All content is independently produced and free from commercial influence.